AP protocol 1

chemotherapy protocol of above compounds; used in the treatment of pleural neoplasm & childhood hepatoblastoma

Also Known As:

AP regimen; PA-CI protocol; PLADO protocol

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - AP protocol 1: 6
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - AP protocol 1: 6
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - AP protocol 1: 6
Inorganic Chemicals: 9
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthacenes
        Anthracyclines: 9423
        Daunorubicin: 2641
        Doxorubicin: 35390
        AP protocol 1: 6
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthacenes
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        Doxorubicin: 35390
        AP protocol 1: 6
Carbohydrates: 22023
- Glycosides: 2119
  - Aminoglycosides: 5131
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        Doxorubicin: 35390
        AP protocol 1: 6

Experts

1.	Chekani, Farid: 1 article (01/2022)
2.	Khandker, Rezaul: 1 article (01/2022)
3.	Limone, Brendan: 1 article (01/2022)
4.	Thiel, Ellen: 1 article (01/2022)
5.	Berjohn, Catherine M: 1 article (09/2019)
6.	Boonchan, Threechada: 1 article (09/2019)
7.	Buathong, Nillawan: 1 article (09/2019)
8.	Burkly, Hana: 1 article (09/2019)
9.	Chann, Soklyda: 1 article (09/2019)
10.	Chaoratanakawee, Suwanna: 1 article (09/2019)

Related Diseases

1.	Oral Ulcer (Mouth Ulcer) 02/01/2015 - "On the 21st day after administration of the first cycle of AP regimen and the 8th day after the initiation of gefitinib treatment, she developed an acne-like rash, oral ulcer, and conjunctivitis, which later became blisters and ultimately denuded. "
2.	Weight Gain 01/01/2022 - "However, this does not appear to be related to the weight gain risk profile of the AP regimen."
3.	Vomiting 10/01/2012 - "The AP regimen can effectively control acute and delayed emesis in the majority patients receiving high-dose CY."
4.	Neoplasms (Cancer) 01/01/2023 - "In the multivariate analysis, significant predictors were identified as follows: de novo or R1/R2 resected tumor on admission before RCT (p = 0.017; hazard ratio [HR] 0.112, 95% confidence interval [CI] 0.019-0.675) and R0 resection after RCT (p = 0.010; HR 0.121, 95% CI 0.024-0.598) for LRFS; female gender (p = 0.042; HR 0.569, 95% CI 0.330-0.979) and liposarcoma histology (p = 0.014; HR 0.436, 95% CI 0.224-0.845) for DFS; liposarcoma histology (p = 0.003; HR 0.114, 95% CI 0.027-0.478) and AP regimen (p = 0.017; HR 0.371, 95% CI 0.165-0.836) for DSS; age ≤ 45 years (p = 0.043; HR 0.537, 95% CI 0.294-0.980) and liposarcoma histology (p = 0.006; HR 0.318, 95% CI 0.141-0.716) for OS, respectively. "
5.	Liposarcoma 01/01/2023 - "In the multivariate analysis, significant predictors were identified as follows: de novo or R1/R2 resected tumor on admission before RCT (p = 0.017; hazard ratio [HR] 0.112, 95% confidence interval [CI] 0.019-0.675) and R0 resection after RCT (p = 0.010; HR 0.121, 95% CI 0.024-0.598) for LRFS; female gender (p = 0.042; HR 0.569, 95% CI 0.330-0.979) and liposarcoma histology (p = 0.014; HR 0.436, 95% CI 0.224-0.845) for DFS; liposarcoma histology (p = 0.003; HR 0.114, 95% CI 0.027-0.478) and AP regimen (p = 0.017; HR 0.371, 95% CI 0.165-0.836) for DSS; age ≤ 45 years (p = 0.043; HR 0.537, 95% CI 0.294-0.980) and liposarcoma histology (p = 0.006; HR 0.318, 95% CI 0.141-0.716) for OS, respectively. "

Related Drugs and Biologics

1.	Cisplatin (Platino)
2.	Artesunate
3.	Gefitinib (Iressa)
4.	Pemetrexed (MTA)

Related Therapies and Procedures

1.	Neoadjuvant Therapy
2.	Drug Therapy (Chemotherapy)